Mechanistically, PD-L2 is able to activate RhoA-ROCK-LIMK2 and autophagy pathways underlying osteosarcoma invasion and metastasis [62], supporting the biologic relevance of PD-L2 with cancer progression. Here, LIMK2 is linked to osteosarcoma.